Ascletis to Present Study Results at ObesityWeek 2025
Ascletis Pharma Inc. announces multiple poster presentations of its obesity assets, including ASC30, ASC30 Injection, and the combination of ASC31 and ASC47, at ObesityWeek 2025 in Atlanta, Georgia.
- Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30.
- ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation.
- Combination of ASC31 and ASC47.
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity
Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m.
Author's summary: Ascletis presents obesity study results.